StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.11+0.88 (+0.93%)

Close on Nov 17, 2026Market cap $14.95BP/E 73.2Yield –

Kiniksa Pharmaceuticals International r&d expenses

Research and development expenses are spending on new products and technology.

Kiniksa Pharmaceuticals International's R&D Expenses for the twelve months ending Sep 30, 2026 was $135.77M, up 39.3% year over year. For fiscal 2025 it was $96.85M, down 13.2% from the year before. The highest annual figure on record is $135.00M in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$96.85M-13.2%
FY2024Dec 31, 2024$111.62M+46.7%
FY2023Dec 31, 2023$76.10M+16.2%
FY2022Dec 31, 2022$65.49M-34.0%
FY2021Dec 31, 2021$99.30M-11.4%
FY2020Dec 31, 2020$112.04M-17.0%
FY2019Dec 31, 2019$135.00M+55.9%
FY2018Dec 31, 2018$86.60M+53.7%
FY2017Dec 31, 2017$56.36M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$32.79M+35.7%
Q2 FY2026Jun 30, 2026$40.90M+118.1%
Q1 FY2026Mar 31, 2026$27.48M+42.2%
Q4 FY2025Dec 31, 2025$34.61M-1.7%
Q3 FY2025Sep 30, 2025$24.17M-7.3%
Q2 FY2025Jun 30, 2025$18.75M-21.9%
Q1 FY2025Mar 31, 2025$19.33M-26.6%
Q4 FY2024Dec 31, 2024$35.22M+75.6%
Q3 FY2024Sep 30, 2024$26.06M+52.3%
Q2 FY2024Jun 30, 2024$24.02M+1.1%
Q1 FY2024Mar 31, 2024$26.33M+73.6%
Q4 FY2023Dec 31, 2023$20.05M+39.3%
Q3 FY2023Sep 30, 2023$17.11M+3.8%
Q2 FY2023Jun 30, 2023$23.77M+72.2%
Q1 FY2023Mar 31, 2023$15.17M-27.1%
Q4 FY2022Dec 31, 2022$14.39M-47.5%
Q3 FY2022Sep 30, 2022$16.49M-14.3%
Q2 FY2022Jun 30, 2022$13.80M-42.4%
Q1 FY2022Mar 31, 2022$20.82M-27.4%
Q4 FY2021Dec 31, 2021$27.43M-26.6%
Q3 FY2021Sep 30, 2021$19.24M-38.8%
Q2 FY2021Jun 30, 2021$23.95M+7.3%
Q1 FY2021Mar 31, 2021$28.68M+37.2%
Q4 FY2020Dec 31, 2020$37.40M+63.4%
Q3 FY2020Sep 30, 2020$31.42M+42.7%
Q2 FY2020Jun 30, 2020$22.32M-27.6%
Q1 FY2020Mar 31, 2020$20.90M-64.7%
Q4 FY2019Dec 31, 2019$22.89M-36.6%
Q3 FY2019Sep 30, 2019$22.01M+6.6%
Q2 FY2019Jun 30, 2019$30.85M+79.3%
Q1 FY2019Mar 31, 2019$59.25M+369.1%
Q4 FY2018Dec 31, 2018$36.12M+20.7%
Q3 FY2018Sep 30, 2018$20.64M+47.4%
Q2 FY2018Jun 30, 2018$17.20M+85.5%
Q1 FY2018Mar 31, 2018$12.63M–
Q4 FY2017Dec 31, 2017$29.93M–
Q3 FY2017Sep 30, 2017$14.01M–
Q2 FY2017Jun 30, 2017$9.27M–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?